Ono Pharmaceutical Co., Ltd.

4528

JP3197600004

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-26 am EDT			5-day change	1st Jan Change
2,300 ^JPY	+1.34%		+2.77%	-8.59%

Mar. 21	ONO Pharmaceuticals, Co., Ltd. Announces Enrollment is Complete for the First Arm of the PROSPECT Study of Tirabrutinib in U.S. Patients with Relapsed or Refractory PCNSL	CI
Mar. 14	Sibylla Biotech Enters Strategic Drug Discovery Collaboration with Ono Pharmaceutical Co., Ltd. in Central Nervous System Disorders	CI

Ono Pharmaceutical : U.S. Food and Drug Administration Approves Opdivo® (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

March 11, 2024 at 10:08 pm EDT

This material is intended to notify the press release issued on March 7 (local time) by Bristol Myers Squibb, our license partner for Opdivo.
Please click https://www.bms.com/media/press-releases.html for the original press release.

Attachments

Original Link
Permalink

Disclaimer

ONO Pharmaceutical Co. Ltd. published this content on 12 March 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 March 2024 02:07:09 UTC.

Latest news about Ono Pharmaceutical Co., Ltd.

ONO Pharmaceuticals, Co., Ltd. Announces Enrollment is Complete for the First Arm of the PROSPECT Study of Tirabrutinib in U.S. Patients with Relapsed or Refractory PCNSL	Mar. 21	CI
Sibylla Biotech Enters Strategic Drug Discovery Collaboration with Ono Pharmaceutical Co., Ltd. in Central Nervous System Disorders	Mar. 14	CI
Ono Pharmaceutical Co., Ltd. Enters into A University-Wide, Research Alliance Agreement with Harvard University	Mar. 11	CI
Jefferies Adjusts Ono Pharmaceutical’s Price Target to 2,400 Yen From 2,300 Yen, Keeps at Hold	Mar. 11	MT
Tranche Update on Ono Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 25, 2023.	Mar. 04	CI
Ono Pharmaceutical Co., Ltd.'s Equity Buyback announced on July 25, 2023, has closed with 18,732,400 shares, representing 3.88% for ¥49,999.75 million.	Feb. 29	CI
Transcript : Ono Pharmaceutical Co., Ltd. - Special Call	Feb. 21
InveniAI LLC Announces Collaboration with Ono Pharmaceutical for Target Discovery	Feb. 19	CI
Shattuck Labs Collaborates With Ono Pharmaceutical to Develop Fusion Proteins	Feb. 14	MT
Shattuck Strikes Joint Development Deal With Japan's Ono Pharma	Feb. 13	DJ
Tranche Update on Ono Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 25, 2023.	Jan. 05	CI
Ono Pharmaceutical Co., Ltd. Enters into Collaboration Agreement with EVQLV to Generate Novel Antibodies against Multiple Targets Utilizing EVQLV's AI-powered Antibody Design Engine for Development of Innovative Antibody Drugs	Dec. 21	CI
Ono Enters into Research Collaboration with UK Dementia Research Institute	Dec. 21	CI
Biomed X Institute and Ono Pharmaceutical Launch New Collaboration in Cancer Research	Dec. 19	CI
Ono Pharmaceutical Co., Ltd.(TSE:4528) dropped from TOPIX 100 INDEX (NEW INDEX SERIES)	23-10-30	CI
Turbine Simulated Cell Technologies Ltd. Establishes Research Collaboration with Ono Pharmaceutical Co., Ltd. to Identify and Validate Novel Oncology Targets	23-10-24	CI
Tranche Update on Ono Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 25, 2023.	23-10-02	CI
Ono Pharmaceutical Co., Ltd. Enters into A Drug Discovery Collaboration Agreement with Adimab to Discover Novel Antibody Drugs in the Oncology Field	23-09-27	CI
Twist Bioscience Partners With Ono Pharmaceutical on Drug Discovery	23-08-31	MT
Ono Pharmaceutical Co., Ltd. announces an Equity Buyback for 19,000,000 shares, representing 3.89% for ¥50,000 million.	23-07-24	CI
Ono Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	23-07-24	CI
Jefferies Adjusts Ono Pharmaceutical’s Price Target to 2,300 Yen From 2,500 Yen, Keeps at Underperform	23-05-30	MT
Personalis, National Cancer Center Hospital East, and Ono Collaborate to Better Predict Immunotherapy Response for Rectal Cancer	23-05-16	CI
Ono Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-09	CI
Macomics Ltd and Ono Pharmaceutical Co., Ltd. Partner to Discover and Develop Macrophage-Targeting Antibody Therapy for the Treatment of Cancer	23-03-23	CI

Chart Ono Pharmaceutical Co., Ltd.

Duration

Period

More charts

Company Profile

ONO PHARMACEUTICAL CO., LTD. is a Japan-based company primarily engaged in the manufacture and sale of pharmaceuticals. The Company operates in one business segment. The Pharmaceutical segment involves in the manufacture and sale of drugs for medical and general use. The Company also involves in the clinical development, introduction and derivation of pharmaceuticals.

Sector

Pharmaceuticals

Calendar

2024-05-08 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Ono Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

2,300 JPY

Average target price

2,656 JPY

Spread / Average Target

+15.47%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
ONO PHARMACEUTICAL CO., LTD.	-8.59%	6.86B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.62%	43.34B
OTSUKA HOLDINGS CO., LTD.	+20.44%	21.96B
SANDOZ GROUP AG	+10.86%	14.09B
CIPLA LIMITED	+13.07%	13.64B
ZYDUS LIFESCIENCES LIMITED	+37.46%	11.43B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+8.46%	5.22B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-4.29%	4.71B

Generic Pharmaceuticals

Ono Pharmaceutical Co., Ltd.

Equities

4528

JP3197600004

Pharmaceuticals

Ono Pharmaceutical : U.S. Food and Drug Administration Approves Opdivo® (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

EPS Revisions